![Laura Stoppel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Stoppel
Directeur/Membre du Conseil chez
ARTIVA BIOTHERAPEUTICS, INC.
Fortune : 27 520 $ au 31/07/2026
Profil
Laura Stoppel currently holds multiple director and independent director positions at Acumen Pharmaceuticals, Inc. (since 2020), Nimbus Therapeutics LLC (since 2020), CellCentric Ltd. (since 2024), Verdiva Bio, Inc. (since 2024), Artiva Biotherapeutics, Inc. (since 2020), Indapta Therapeutics, Inc. (since 2022), and International Rett Syndrome Foundation (since 2023).
Additionally, Dr. Stoppel is a partner at RA Capital Management LP (since 2016, partner title since 2024) and a principal at RA Capital Management LP (Private Equity) since 2016, with the principal title starting in 2020.
Education history includes an undergraduate degree from Harvard University conferred in 2008 and a doctorate from the Massachusetts Institute of Technology conferred in 2016.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/06/2026 | 12 800 ( 0,02 % ) | 27 520 $ | 31/07/2026 | |
| 20/07/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Laura Stoppel
| Sociétés | Poste | Début |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/06/2020 |
| ACUMEN PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/11/2020 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Private Equity Investor | 01/12/2020 |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Directeur/Membre du Conseil | 01/10/2020 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Directeur/Membre du Conseil | 01/01/2022 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Analyst-Equity | 01/10/2016 |
International Rett Syndrome Foundation | Directeur/Membre du Conseil | 01/07/2023 |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Directeur/Membre du Conseil | 01/07/2024 |
Formation de Laura Stoppel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Acumen Pharmaceuticals, Inc.
 Acumen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops medicines and diagnostics for Alzheimer's disease | Health Technology |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical stage biotech company that develops molecule medicines for diseases like cancer, immune disorders and metabolic conditions | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CellCentric Ltd.
CellCentric Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule inhibitors for cancer | Health Technology |
International Rett Syndrome Foundation | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Health Technology |
